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1  | INTRODUC TION
MRONJ	is	a	potentially	serious	complication	of	anti‐resorptive	(AR)	
treatment	in	patients	with	skeletal	metastases	due	to	various	cancers	
as	well	as	osteoporosis	(Campisi	et	al.,	2014).	MRONJ	may	also	develop	
in	anti‐resorptive‐naive	individuals	exposed	to	a	variety	of	anti‐angio‐
genic	agents	(Mohamed,	Nielsen,	&	Schiodt,	2018;	Nicolatou‐Galitis,	
Kouri,	et	al.,	2019;	Pimolbutr,	Porter,	&	Fedele,	2018).	MRONJ	may	
lead	to	a	reduced	quality	of	life	due	to	jaw	bone	infections,	chronic	
pain,	tooth	loss,	impaired	function,	and	disfigurement.
Since	the	first	report	by	Marx,	2003	(Marx,	2003),	the	number	
of	 cases	 and	 relevant	 publications	 has	 increased	 significantly	 (M.	
Schiodt,	 PubMed	 Search	 26.6.2019,	 unpublished).	 Despite	 signifi‐
cant	progress	in	our	knowledge	of	the	disease,	there	remain	a	number	
of	controversial	aspects	that	are	of	high	relevance	to	researchers,	cli‐
nicians,	and	not	least	patients.	The	European	Task	Force	on	MRONJ	
comprises	of	a	multidisciplinary	group	of	European	clinical	 investi‐
gators	with	a	 special	 interest	 in	 the	diagnosis	and	management	of	
MRONJ	 and	 a	 track	 record	 of	 relevant	 research	 and	 publications,	
who	considered	the	current	controversies	on	MRONJ	a	reason	for	
academic	 concern,	 a	 potential	 threat	 to	 patients,	 and	 a	 limitation	
for	better	research.	The	group	met	up	in	two	separate	workshops	in	
order	to	(a)	highlight	some	of	the	most	controversial	aspects	of	cur‐
rent	knowledge	on	MRONJ	and	(b)	provide	an	expert	opinion‐based	
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The	workshop	group	members	are	all	engaged	in	MRONJ	treatment	and	research	and	account	for	a	total	of	159	publications	(including	some	shared	publications).	In	the	following,	the	
number	of	published	papers	on	MRONJ	for	each	author	is	listed	in	brackets.	
Morten	Schiodt	(21),	Sven	Otto	(40),	Stefano	Fedele	(16),	Alberto	Bedogni	(26),	Ourania	Nicolatou‐Galitis	(16),	Roman	Guggenberger	(3),	Bente	Brokstad	Herlofson	(19),	Oliver	Ristow	
(17),	Thomas	Kofod	(1).	
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consensus	on	these	topics	with	a	view	to	help	clinicians	making	in‐
formed	decisions	on	patient's	care	and	 inspire	future	 investigators	
to	design	better	 clinical	 studies.	 The	Group	 agreed	 to	 focus	upon	
three	highly	controversial	aspects	of	MRONJ:	(a)	definition	and	clas‐
sification,	(b)	risk	factors,	and	(c)	management/treatment	of	MRONJ.
2  | CONTROVERSIES ON DEFINITION AND 
CL A SSIFIC ATION
The	consensus	papers	by	Ruggiero	et	al.	representing	the	American	
Association	of	Oral	and	Maxillofacial	Surgeons	(AAOMS)	(Advisory	
Task	Force	on	Bisphosphonate‐Related	Osteonecrosis	of	 the	 Jaws	
AAOMS,	2007;	S.	L.	Ruggiero	et	al.,	2014;	Ruggiero	et	al.,	2009)	have	
been	 instrumental	 in	 the	process	of	establishing	an	understanding	
and	 acceptance	 of	 a	 widely	 used	 definition	 and	 classification	 of	
MRONJ.	The	most	recent	version	of	the	AAOMS	consensus	(2014)	
includes	(a)	the	MRONJ	case	definition	as	the	presence	of	exposed	
jaw	bone	or	bone	that	can	be	probed	through	an	intraoral	or	extraoral	
fistula(e)	 for	at	 least	8	weeks	 in	a	patient	 receiving	anti‐resorptive	
and/or	anti‐angiogenic	therapy	who	had	not	received	radiotherapy	
to	the	head	and	neck,	and	(b)	a	disease	classification	into	4	clinical	
stages	(stage	0‐3).	The	most	notable	change	introduced	in	the	2014	
AAOMS	consensus	was	the	modified	MRONJ	definition	so	to	include	
patients	presenting	with	an	intraoral	or	extraoral	fistula(e).	This	im‐
portant	amendment	was	inspired	by	a	number	of	reports	highlight‐
ing	 that	 a	 sub‐group	 of	 patients	 can	 in	 fact	 present	with	MRONJ	
disease	 characterized	 by	 the	 absence	 of	 exposed	 bone	 on	 visual	
inspection	(so‐called	non‐exposed	MRONJ,	 including	the	presence	
of	 an	 intraoral	 fistula,	 mandibular	 fracture,	 dentally	 unexplained	
pain,	and	swelling,	among	other	manifestations),	and	therefore,	they	
would	not	fulfill	the	case	definition	of	MRONJ	as	suggested	by	the	
initial	version	of	the	AAOMS	consensus	(2007)	(Ascani,	Campisi,	&	
Junquera	Gutierrez,	2014;	Bedogni,	Fusco,	Agrillo,	&	Campisi,	2012;	
Fedele	et	al.,	2015;	S.	Patel	et	al.,	2012;	Schiodt,	Reibel,	Oturai,	&	
Kofod,	2014;	Yarom,	Fedele,	Lazarovici,	&	Elad,	2010).
The	background	was	 the	obviously	different	 interpretations	of	
the	term	“bone	exposure”	by	different	author	groups	and	adjudica‐
tors	in	clinical	and	epidemiological	studies.	Some	authors	regarded	
bone	that	can	be	probed	through	a	fistula	as	exposed	and	diagnosed	
MRONJ	in	the	respective	cases,	while	other	authors	did	not	include	
those	patients.
The	2009	update	of	the	AAOMS	consensus	papers	(Ruggiero	et	
al.,	2009)	partially	addressed	this	issue	as	they	added	the	new	classi‐
fication	stage	(stage	0)	to	include	patients	presenting	with	the	non‐
exposed	variant	of	MRONJ.	However,	 the	MRONJ	case	definition	
remained	 paradoxically	 unchanged,	 therefore	 preventing	 non‐ex‐
posed	MRONJ	cases	to	be	formally	diagnosed,	especially	in	clinical	
trials	and	epidemiological	studies	(Fedele	et	al.,	2015).
Although	the	2014	update	of	the	AAOMS	consensus	represents	a	
notable	improvement,	patients	presenting	with	non‐exposed	MRONJ	
without	fistulas	(e.g.,	dentally	unexplained	pain,	mobile	teeth	not	due	
to	periodontitis,	numbness	of	 the	 lip,	mandibular	 fracture)	continue	
to	remain	excluded	from	MRONJ	case	definition	(Fedele	et	al.,	2015)	
(Table	1	and	2).	There	is	therefore	an	urgent	need	for	expanding	the	
case	definition	of	MRONJ	so	to	encompass	the	other	manifestations	
of	non‐exposed	MRONJ	and	ensure	that	these	patients	can	(a)	be	for‐
mally	diagnosed	and	treated,	and	(b)	be	included	in	clinical	and	epide‐
miological	studies.	The	Group	appreciated	that	this	might	be	a	difficult	
task	 as	 an	 accurate	 case	 definition	 should	 ensure	 the	 exclusion	 of	
etiopathologically	different	disorders	presenting	with	similar	clinical	
manifestations,	 which	 include	 plaque‐related	 gingivitis/periodonti‐
tis,	dental	and	periapical	disease,	benign	fibro‐osseous	lesion	of	the	
jawbones,	chronic	sclerosing	osteomyelitis,	 infectious	osteomyelitis,	
primary	jawbone	malignancy,	metastatic	disease,	and	TMJ	disorders	
(Fedele	et	al.,	2015;	Patel	et	al.,	2012;	Ruggiero	et	al.,	2014;	Schiodt	et	
al.,	2014).	Excluding	these	conditions	as	well	as	describing	the	MRONJ	
lesions	requires	imaging.	The	value	of	imaging	is	described	later	under	
controversies	 on	 management/treatment.	 Some	 authors	 have	 sug‐
gested	that	 that	up	to	one‐quarter	of	MRONJ	patients	can	present	
with	the	non‐exposed	variant	(Fedele	et	al.,	2015).	Although	this	pro‐
portion	 is	expected	 to	be	 somewhat	 reduced	after	 the	 inclusion	of	
fistula	in	the	definition	(2014	AAOMS	paper),	efforts	should	be	made	
to	improve	and	expand	case	definition	so	to	capture	diagnosis	in	these	
patients	including	those	with	non‐exposed	MRONJ	without	fistulas.
The	Group	also	suggested	that	the	requirement	of	8‐week	ob‐
servation	 of	 potential	 MRONJ	 manifestation	 to	 fit	 the	 case	 defi‐
nition	may	no	 longer	be	necessary.	About	one	 third	 to	half	of	 the	
affected	individuals	currently	develop	MRONJ	without	a	history	of	
dental	extraction	or	other	trauma	(Otto,	Pautke,	Van	den	Wyngaert,	
Niepel,	&	Schiødt,	2018),	and	differential	diagnosis	with	other	den‐
tal	and	jawbone	disease	can	be	achieved	without	having	to	wait	for	
8	weeks	(Bedogni	et	al.,	2012).
TA B L E  1  Staging	of	MRONJ.	After	(Ruggiero	et	al.,	2014)
MRONJa Staging
At‐risk	category	No	apparent	necrotic	bone	in	patients	who	have	
been	treated	with	either	oral	or	IV	bisphosphonates
Stage	0	No	clinical	evidence	of	necrotic	bone,	but	non‐specific	clini‐
cal	findings,	radiographic	changes,	and	symptoms
Stage	1	Exposed	and	necrotic	bone,	or	fistulae	that	probe	to	
bone,	in	patients	who	are	asymptomatic	and	have	no	evidence	of	
infection
Stage	2	Exposed	and	necrotic	bone,	or	fistulae	that	probe	to	bone,	
associated	with	infection	as	evidenced	by	pain	and	erythema	in	the	
region	of	the	exposed	bone	with	or	without	purulent	drainage
Stage	3	Exposed	and	necrotic	bone	or	a	fistula	that	probes	to	bone	
in	patients	with	pain,	infection,	and	one	or	more	of	the	following:	
exposed	and	necrotic	bone	extending	beyond	the	region	of	alveo‐
lar	bone	(i.e.,	inferior	border	and	ramus	in	the	mandible,	maxillary	
sinus,	and	zygoma	in	the	maxilla),	resulting	in	pathologic	fracture,	
extraoral	fistula,	oral	antral/oral–nasal	communication,	or	osteoly‐
sis	extending	to	the	inferior	border	of	the	mandible	of	sinus	floor
aExposed	or	probable	bone	in	the	maxillofacial	region	without	resolu‐
tion	for	>8	weeks	in	patients	treated	with	an	anti‐resorptive	and/or	an	
anti‐angiogenic	agent	who	have	not	received	radiation	therapy	to	the	
jaws.	
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3  | CONTROVERSIES ON RISK FAC TORS
According	to	the	literature,	tooth	extraction,	infection,	type	and	dos‐
age	of	AR,	and	duration	of	treatment	are	considered	to	be	risk	factors.
Approximately	half	to	two‐thirds	of	MRONJ	cases	are	reported	
to	develop	 following	a	 tooth	extraction	 (Otto	et	al.,	2018).	Dental	
extraction	was	reported	as	a	main	risk	factor	in	73%	of	the	cases	of	
ONJ	(Nicolatou‐Galitis	et	al.,	2011),	and	historically,	these	cases	have	
been	 identified	as	a	non‐healing	extraction	 socket	 (Bedogni	et	 al.,	
2012).	Accordingly,	the	vast	majority	of	recommendations	on	dental	
treatment	of	patients	on	anti‐resorptive	or	anti‐angiogenic	therapy	
have	included	advice	against	dental	extractions	as	a	mean	to	resolve	
dental	infection	(Khan	et	al.,	2008;	Khosla	et	al.,	2007;	Matsuo	et	al.,	
2014;	Ruggiero	et	al.,	2014;	Yoneda	et	al.,	2010).
However,	a	growing	body	of	evidence	suggests	that	dental	infec‐
tion,	 rather	 than	dental	 extraction	per	 se,	might	 represent	 the	main	
local	risk	factor	for	MRONJ	(Otto	et	al.,	2015;	Panya	et	al.,	2017;	Saia	
et	al.,	2010).	For	example,	a	2011	case–control	study	with	three	dental	
practice‐based	research	networks	in	the	United	States	found	that	the	
likelihood	of	developing	osteonecrosis	was	higher	 (almost	double)	 in	
patients	with	a	history	of	suppuration	compared	to	those	with	a	history	
of	dental	extractions	(OR	11.9	vs.	6.6)	(Barasch	et	al.,	2011).	It	is	also	
increasingly	 reported	 that	 dental	 extractions	 in	 patients	 exposed	 to	
anti‐resorptive	therapy	usually	do	not	translate	into	MRONJ	develop‐
ment,	when	tooth	extraction	is	performed	using	alveolectomy	and	pri‐
mary	surgical	mucosal	closure	(Heufelder	et	al.,	2014;	Otto	et	al.,	2015).	
Thus,	surgical	intervention	per	se	should	not	be	overemphasized	as	the	
main	 risk	 factor	 for	MRONJ	development.	Similarly,	 it	has	been	sug‐
gested	that	infection	around	the	implants	(peri‐implantitis)	represents	a	
notable	risk	factor	for	MRONJ	development	(Giovannacci	et	al.,	2016;	
Troeltzsch	et	al.,	2016).	This	 is	also	 in	 line	with	the	high	success	rate	
after	surgery	on	the	jawbone	to	cure	MRONJ	lesions	(see	later).
The	Group	suggested	that	dental	 infection	might	currently	be	a	
more	common	and	relevant	risk	factor	for	MRONJ	compared	to	ex‐
traction	and	that	a	notable	proportion	of	MRONJ	cases	believed	to	
have	been	triggered	by	dental	extraction	 in	 fact	 represent	cases	of	
non‐exposed	MRONJ	 that	 had	 already	 developed	 because	 of	 den‐
tal/periodontal	 infection	 before	 the	 actual	 extraction	 took	 place.	
Recent	 studies	have	 reported	 the	presence	of	histologically	proven	
alveolar	 necrotic	 bone	 associated	with	dental/periodontal	 infection	
at	the	time	of	the	extraction	of	teeth	(Nicolatou‐Galitis	et	al.,	2015;	
Nicolatou‐Galitis,	Schiødt,	et	al.,	2019).	Similarly,	animal	studies	have	
reported	that	MRONJ	can	develop	to	areas	of	periodontal	infection	in	
the	absence	of	dental	extraction	surgery	(Nowicki	et	al.,	2019;	Otto	et	
al.,	2017).	Although	evidence	remains	not	robust	and	further	well‐de‐
signed	clinical	trials	are	needed,	the	Group	suggested	that	patients	on	
anti‐resorptive	therapy	should	not	be	declined	dental	extractions	for	
the	treatment	of	recurrent	dental/periodontal	infections	that	cannot	
be	resolved	or	have	failed	to	resolve	with	restorative	treatment,	as	the	
persistence	of	the	infection	per	se	represents	a	notable	risk	factor	for	
MRONJ	development.	The	group	recommended	that	when	needed,	
tooth	extractions	should	be	performed	with	raising	a	muco‐periosteal	
flap,	alveolectomy,	smoothing	of	bone	edges,	mobilization	of	the	flap,	
and	primary	tension‐free	closure	of	the	alveolus	with	tight	suturing.
The	Group	also	highlighted	 the	 importance	of	appropriate	strati‐
fication	of	the	risk	of	MRONJ	development	based	on	the	type,	dose,	
and	administration	route	of	anti‐resorptive	medication.	There	is	robust	
evidence	that	drug‐related	factors	associated	with	an	increased	risk	of	
MRONJ	development	 include	nitrogen‐containing	structure,	cumula‐
tive	high	dose,	use	 in	cancer	 setting,	and	 intravenous	administration	
(Abt,	2017;	Malden	&	Lopes,	2012;	Ruggiero	et	al.,	2014;	Vahtsevanos	
et	al.,	2009).	However,	 it	should	be	emphasized	that	 intravenous	ad‐
ministration	 of	 bisphosphonate	 per	 se	 should	 not	 be	 automatically	
considered	an	indicator	of	the	high	risk	of	MRONJ	development.	For	
example,	 some	osteoporosis	 patients	 receive	 yearly	 intravenous	bis‐
phosphonates;	however,	because	the	cumulative	dosage	remains	low,	
their	risk	of	developing	MRONJ	is	also	low.	Furthermore,	a	low	dose,	
usually	 quarterly	 or	 half‐yearly,	 of	 prophylactic	 intravenous	 bisphos‐
phonates	has	been	recently	 introduced	in	the	management	of	breast	
cancer	 patients	without	metastases	 (adjuvant	 therapy),	 and	 this	 has	
been	reported	to	be	associated	with	notably	lower	risk	of	MRONJ	de‐
velopment	(Patel	et	al.,	2018;	Rugani	et	al.,	2014).	The	Group	suggested	
that,	in	order	to	optimize	risk	assessment	and	management	of	patients	
on	anti‐resorptive	therapy,	 it	 is	 important	to	highlight	to	all	clinicians	
and,	in	particular	in	the	dental	setting,	that	the	risk	of	MRONJ	devel‐
opment	is	mostly	associated	with	high	cumulative	dosage	of	nitrogen‐
containing	bisphosphonates.	(Fung	et	al.,	2017;	Ruggiero	et	al.,	2014).
4  | CONTROVERSIES ON MANAGEMENT/
TRE ATMENT
Expert	 opinion‐based	 recommendations	 for	 the	 management	 of	
MRONJ	 are	 included	 in	 the	 AAOMS	 position	 papers	 (Advisory	
Task	Force	on	Bisphosphonate‐Related	Osteonecrosis	of	 the	 Jaws	
TA B L E  2  Mismatch	between	the	2014	AAOMS	case	definition	
criteria	(Ruggiero	et	al.,	2014)	and	clinical	manifestations	of	MRONJ	
(modified	from	Fedele	et	al.	(2015))
Clinical manifestations
Included in the 
AAOMS definition
Exposed	MRONJ
Frank	bone	exposure Yes
Non‐exposed	MRONJ
Sinus/Fistula	tracta Yes
Bone	paina No
Bone	swellinga No
Gingival	swellinga No
Tooth	mobilitya No
Mandibular	fracturea No
Maxillary	sinus	Paina No
Lower	lip	numbness/dysaesthesiaa No
aNot	caused	by	dental	or	other	jawbone	diseases,	which	should	be	
ruled	out	with	clinical	and	radiological	investigations	before	suspecting	
MRONJ	diagnosis.	
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AAOMS,	2007;	Ruggiero	et	al.,	2009,	2014).	The	Group	highlighted	
that	 AAOMS	 treatment	 recommendations,	 which	 are	 based	 on	 a	
clinically	driven	staging	system,	may	fail	 to	reflect	the	actual	bone	
extension	of	MRONJ	disease,	with	the	risk	of	assigning	patients	to	
“inappropriate”	treatments	(Bedogni	et	al.,	2014).
Accordingly,	 some	 authors	 advocated	 the	 adoption	 of	 treat‐
ments	 based	 also	 on	 the	 radiological	 aspects	 of	MRONJ	 disease	
(Campisi	et	al.,	2014)	 in	order	 to	pick	up	early	signs	of	disease	or	
base	 therapeutic	decisions	on	accurate	assessment	of	disease	ex‐
tent.	 However,	 there	 remains	 no	 consensus	 on	 the	 efficacy	 of	
different	radiological	 imaging	modalities	 (e.g.,	CT,	MRI,	or	nuclear	
imaging)	in	assessing,	with	high	accuracy,	the	“true”	MRONJ	disease	
extent.	(Bisdas	et	al.,	2008;	Devlin	et	al.,	2018).	A	number	of	studies	
have	compared	specific	imaging	modalities	and	found	inconsistent	
results	 in	 terms	 of	 overestimation/underestimation	 of	 the	 exten‐
sion	of	MRONJ	(Guggenberger	et	al.,	2013;	Stockmann	et	al.,	2010).
The	group	advised	that	clinicians	should	be	careful	in	adopting	treat‐
ment	recommendations	that	are	solely	based	on	clinical	assessment	of	
MRONJ	patients,	and	that	further	imaging	studies	are	needed	in	order	
to	study	the	extension	of	necrotic	bone	disease	in	MRONJ	patients.
The	group	also	highlighted	the	current	controversy	on	surgical	
management	 of	 MRONJ	 patients.	 The	 AAOMS	 recommendations	
suggest	 generally	 non‐surgical	 treatment	 for	 stages	 1	 and	 2,	 and	
performing	surgical	debridement/resection	of	necrotic	bone	only	for	
stage	3	MRONJ	patients	(Advisory	Task	Force	on	Bisphosphonate‐
Related	 Osteonecrosis	 of	 the	 Jaws	 AAOMS,	 2007;	 Salvatore	 L.	
Ruggiero	et	al.,	2009;	Ruggiero	et	al.,	2014).
However,	there	is	an	increasing	body	of	evidence	suggesting	that	
surgical	removal	of	necrotic	bone	might	be	curative	in	patients	with	
all	MRONJ	stages	(Aljohani	et	al.,	2019;	Otto	et	al.,	2018;	Ristow	et	
al.,	 2018),	where	 cure	 is	 defined	as	 long‐term	 resolution	of	 symp‐
toms	and	complete	mucosal	closure	(absence	of	residual	bone	expo‐
sure).	Other	studies	have	documented	high	success	rate	of	surgical	
treatment	compared	to	non‐surgical	treatment	(Aljohani	et	al.,	2019;	
Hauer	et	al.,	2019;	Yamada	et	al.,	2018).
A	 recent	 study	 also	 suggests	 that	 non‐surgical	 therapy	might	
lead	 to	 progression	 of	 MRONJ	 disease.	 Ristow	 et	 al.	 (2019)	 de‐
scribed	 a	 longitudinal	 study	 of	 92	 patients	with	 stage	 1	MRONJ	
who	 were	 initially	 treated	 by	 using	 a	 standardized	 conservative	
(non‐surgical)	 protocol	 consisting	 of	 antimicrobial	 mouth	 rinsing	
and	 gel	 application	 (with	 chlorhexidine).	 The	 authors	 reported	
that	only	8	patients	(8.7%)	showed	complete	mucosal	healing	and	
resolutions	 of	 symptoms	 whereas	 the	 remaining	 84	 (91.3%)	 had	
persistent	exposed	jaw	bone	at	the	end	of	the	observation	period	
(15.6	months).	Among	these	84	patients,	67	(80%)	showed	progres‐
sion	of	their	MRONJ	disease	(upshift	in	AAOMS	stage	from	1	to	2	
or	3),	which	eventually	led	to	extensive	bone	and/or	tooth	loss	in	
28	cases	(Ristow	et	al.,	2019).	The	group	highlighted	that,	although	
well‐designed	 comparative	 trials	 are	 required,	 there	 is	 increasing	
evidence	 suggesting	 that	 surgical	 removal	 of	 the	 necrotic	 bone	
might	 provide	 long‐lasting	 benefits	 to	MRONJ	 patients	 in	 terms	
of	resolving	symptoms,	obtaining	mucosal	healing,	and	preventing	
further	 progression	 of	 necrotic	 bone	 disease.	With	 this	 growing	
body	of	evidence,	a	number	of	clinicians	have	shifted	their	thera‐
peutic	approach	from	conservative	(non‐surgical)	to	upfront	surgi‐
cal	treatment.
5  | RECOMMENDATIONS
Based	 on	 the	 discussion	 points	 summarized	 above,	 the	 group	 has	
produced	a	number	of	consensus	key	statements	and	recommenda‐
tions	so	to	inform	clinicians	and	advice	researchers,	as	a	first	step	of	
reaching	solutions.
5.1 | Key statements and recommendations relevant 
to definition and classifications of MRONJ
•	 Current	widely	adopted	definition	does	not	 identify	all	patients	
affected	by	MRONJ
•	 The	current	description	of	stage	0	is	controversial,	does	not	fulfill	
the	definition	of	the	disease,	and	may	be	misleading	and	difficult	
to	interpret.
•	 Stage	 0	 of	 the	 AAOMS	 classification	 is	 a	 diagnostic	 challenge,	
as	 there	 are	 overlaps	 with	 dental	 and	 non‐dental	 diseases.	
Stage	 0	 may	 ultimately	 need	 confirmation	 by	 imaging	 and/or	
histopathology.
•	 Cases	of	non‐exposed	MRONJ	without	fistula	should	be	included	
in	 the	 definition,	 possibly	 in	 terms	 of	 suspected	 or	 probable	
MRONJ	after	ruling	out	other	dental	and	non‐dental	disease.	The	
only	 ultimate	 proof	 of	 non‐exposed	MRONJ	 might	 be	 the	 his‐
topathologic	 confirmation	of	necrotic	bone.	Decision	on	biopsy	
should	be	taken	on	an	individual	basis.
•	 The	 definition	 criterion	 of	 8‐week	 bone	 exposure/probing	 of	
bone	does	not	apply	to	all	cases	and	may	delay	diagnosis	and	con‐
sequently	treatment.
•	 The	role	of	imaging	in	the	definition	and	classification	of	MRONJ	
needs	further	refinement.	Imaging	may	aid	in	diagnosis	(especially	
for	non‐exposed	cases)	 and	help	determining	disease	extension	
and	planning	treatment.
•	 Present	 classification/staging	 does	 not	 adequately	 capture	 the	
extension	 and	 severity	 of	MRONJ	 lesions.	 This	may	 potentially	
affect	treatment	and	prognosis.
5.2 | Key statements and recommendations 
relevant to risk factors for MRONJ
•	 Tooth	 extraction	 does	 not	 automatically	 translate	 into	 an	 in‐
creased	risk	of	developing	MRONJ,	as	certain	surgical	procedures	
notably	reduce	the	risk.
•	 The	 reported	 high	 risk	 of	 developing	 MRONJ	 after	 tooth	 ex‐
traction	might	 be	 related	 to	 an	 underlying	 pre‐existing	 dental/
periodontal	infection	rather	than	to	the	surgery	per	se.
•	 The	 risk	 of	 developing	 MRONJ	 is	 not	 related	 to	 the	 way	 of	
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administration	as	single	factor;	an	accurate	risk	assessment	should	
include	an	evaluation	of	 the	cumulative	dosage	and	duration	of	
anti‐resorptive	 treatment.	 Typically,	 high‐dose	 anti‐resorptive	
therapy	 given	 to	 cancer	 patients	with	metastases	 is	 associated	
with	higher	risk	of	MRONJ	development	as	compared	to	low‐dose	
therapy	given	to	osteoporosis	patients.
5.3 | Key statements and recommendations 
relevant to management/treatment of MRONJ
•	 Because	 there	 is	 no	 accurate	 staging	 system	 reflecting	 the	 ex‐
tension	of	MRONJ	bone	disease,	 it	 is	problematic,	 and	possibly	
misleading,	to	inform	treatment	recommendations	on	the	basis	of	
currently	available	staging	systems.
•	 The	 term	 “conservative	 treatment”	 is	used	 inconsistently	 in	 the	
literature	and	might	 include	a	number	of	different	 interventions	
ranging	from	topical	antimicrobial	mouthwashes	to	removal	of	su‐
perficial	loose	sequestra.
•	 The	group	recommends	using	the	terms	non‐surgical	versus	surgi‐
cal	treatment.
•	 Recent	 literature	suggests	that	non‐surgical	treatment	may	 lead	
to	disease	progression.
•	 Surgical	treatment	is	superior	to	non‐surgical	management	in	pro‐
moting	long‐term	mucosal	healing	as	well	as	absence	of	symptoms	
or	radiological	signs	indicative	of	bone	necrosis.
•	 If	the	aim	of	treatment	is	reduction	of	symptoms	(pain)	and	con‐
trol	of	infection,	non‐surgical	treatment	may	be	a	valid	manage‐
ment	option.	This	 seems	particularly	 appropriate	 in	 frail	 elderly	
patients	and	in	end‐of‐life	oncology	palliative	setting.
•	 Early	surgical	intervention	on	localized	disease	may	prevent	pro‐
gression	and	the	need	for	subsequent	extensive	surgery	(consider	
to	treat	surgically	and	early).
6  | GENER AL SUMMARY
The	Group	has	highlighted	a	number	of	controversial	aspects	of	cur‐
rent	knowledge	and	practice	relevant	to	MRONJ,	which	have	the	po‐
tential	to	affect	clinical	management	of	patients	as	well	as	research.	
The	Groups	suggest	that	key	statement	and	recommendations	pre‐
sented	in	this	paper	might	represent	a	useful	tool	so	to	stimulate	a	
proactive	discussion	and	inspire	new	and	better‐designed	research,	
as	first	step	to	reach	a	consensus	and	improve	the	management	of	
patients	with	MRONJ.
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